

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. Contents lists available at ScienceDirect



Synthetic and Systems Biotechnology



journal homepage: www.keaipublishing.com/en/journals/synthetic-and-systems-biotechnology

Review Article

Heparin mimetics as potential intervention for COVID-19 and their bio-manufacturing



^a Department of Cardiothoracic Surgery, Children's Hospital of Nanjing Medical University, Nanjing, 210093, China

^b State Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai, 200237, China

^c Division of Chemistry and Analytical Science, Key Laboratory of Chemical Metrology and Applications on Nutrition and Health for State Market Regulation, National

Institute of Metrology, Beijing, 100029, China

^d State Key Laboratory of Microbial Metabolism and School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai, 200240, China

^e Glycochemistry & Glycobiology Lab, Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China

^f International Research Center for Soft Matter, Beijing University of Chemical Technology, Beijing, 100029, China

^g Department of Medical Biochemistry and Microbiology, University of Uppsala, Uppsala, Sweden

ARTICLE INFO

Keywords: Heparin Biosynthesis Biological activities Bio-production

ABSTRACT

The COVID-19 pandemic has caused severe health problems worldwide and unprecedented decimation of the global economy. Moreover, after more than 2 years, many populations are still under pressure of infection. Thus, a broader perspective in developing antiviral strategies is still of great importance. Inspired by the observed multiple benefits of heparin in the treatment of thrombosis, the potential of low molecular weight heparin (LMWH) for the treatment of COVID-19 have been explored. Clinical applications found that LMWH decreased the level of inflammatory cytokines in COVID-19 patients, accordingly reducing lethality. Furthermore, several *in vitro* studies have demonstrated the important roles of heparan sulfate in SARS-CoV-2 infection and the inhibitory effects of heparin and heparin mimetics in viral infection. These clinical observations and designed studies argue for the potential to develop heparin mimetics as anti-SARS-CoV-2 drug candidates. In this review, we summarize the properties of heparin as an anticoagulant and the pharmaceutical possibilities for the treatment of virus infection, focusing on the perspectives of developing heparin mimetics. The ultimate goal is to pave the eminent need for exploring novel compounds to treat coronavirus infection-caused diseases.

1. Introduction

Coronavirus is a family of RNA viruses that infect the respiratory tract system. The ongoing COVID-19 (coronavirus disease 2019) pandemic has caused more than 500 million human infections, including at least 6 million deaths worldwide (as of Apr. 15, 2022), and led to unprecedented decimation of the global economy [1]. COVID-19 is caused by the highly transmissible and pathogenic SARS-CoV-2 RNA virus species with a high fatality rate [2]. The phylogenetic network of

SARS-CoV-2 genomes sampled worldwide revealed closely related evolutionary selection in their human hosts [3]. It should be noted that, within about 2 years, SARS-CoV-2 has already resulted in several evolutionary variants different from the original isolate spreading rapidly over the global areas [4], from Alpha to Delta to the latest globally spreading Omicron. Unfortunately, it is highly possible that Omicron is not the last variant of SARS-CoV-2 [5,6].

In advanced stage of COVID-19, vascular leakage, abnormal coagulopathy and excessive inflammation are the major complications

¹ The authors contributed to this work equally.

https://doi.org/10.1016/j.synbio.2022.10.002

Received 14 July 2022; Received in revised form 26 September 2022; Accepted 5 October 2022 Available online 23 October 2022

2405-805X/© 2022 The Authors. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co. Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).



Peer review under responsibility of KeAi Communications Co., Ltd.

^{*} Corresponding author.

^{**} Corresponding author.

^{***} Corresponding author. Department of Cardiothoracic Surgery, Children's Hospital of Nanjing Medical University, Nanjing, 210093, China. *E-mail addresses: Jianglan@ecust.edu.cn* (L. Jiang), dingkan@simm.ac.cn (K. Ding), liuxueting@ecust.edu.cn (X. Liu).

leading to rapid deterioration and death of COVID-19 patients. Furthermore, a progressive alteration of some inflammatory and coagulative parameters was observed in this stage, leading to an increased risk of both arterial and venous thrombosis [7-9]. Thus, anticoagulation has been proposed as prognostically significant for reducing mortality in COVID-19 treatment [10]. Heparin or low molecular weight heparins (LMWHs) are the mostly used anticoagulant for the prevention and treatment of thrombosis, therefore have been recommended by WHO to apply to moderate-severe COVID-19 patients [10-15]. In addition, heparin also shows 'side' effects, including attenuation of inflammatory reaction and acting as a "trap" to bind the virus [16]. Though these non-anticoagulant effects of heparin are beneficial to patients, a dosage of heparin must be tightly regulated to avoid the risk of bleeding complications. To overcome this potential adverse effect, heparin mimetics with a weakened anticoagulant effect but more potent anti-inflammatory and antiviral activity are attracting attention [17]. To pave the rapid progress in developing non-anticoagulant heparin mimetics, a number of approaches are in the process.

This review summarizes the functional properties of heparin in treating thrombosis and COVID-19 patients and the underlying mechanisms of heparin's beneficial effects in addition to its anticoagulant activity. Production of heparin and heparin mimetics via chemical synthesis, chemoenzymatic synthesis, and the current understandings of the biosynthesis of heparin as well as efforts toward the bioengineered production by microbial cell factories are discussed. Finally, synthetic biology approaches are highlighted as the most efficient strategy for the future supply of heparins.

2. Biological activities of heparin

2.1. Anticoagulation

Heparin was the first glycosaminoglycans (GAGs) molecule discovered, originally isolated from dog liver [18]. A few decades after this discovery, the clinical application of heparin as an anticoagulant was introduced. However, the knowledge regarding the molecular structure and functional mechanism of heparin's anticoagulation activity was utterly lacking. The breakthrough came from 1970 to 1980, when the unique pentasaccharide sequence in heparin chains was identified (Fig. 1). Since then, it has been clarified that the anticoagulation activity of heparin is through a specific interaction between the pentasaccharide sequence and antithrombin (AT), an endogenous anticoagulant protein inhibiting several coagulation factors [19,20] (Fig. 2). This finding significantly promoted the application of heparin and the generation of low molecular weight heparin (LMWH).

It should be pointed out that heparin is currently isolated from animal tissues, mainly porcine intestinal mucosa or bovine lung. This animal-derived medicine is highly heterogenous and has an average molecular weight of 14–15 kDa, leading to poor pharmacokinetics and clinical inconvenience in dosage. Moreover, the macromolecular property of heparin tends to be immunogenic, causing severe side effects, e. g., heparin-induced thrombocytopenia (HIT) [21]. LMWH is generated by partial degradation (enzymatic or chemical) of heparin, resulting in 4–5 kDa fragments. LMWH has several advantages over full-length heparin, including better pharmacokinetics, easier dosage and higher safety. Regardless of the drawbacks of animal resources, more than 100 years after its discovery, this potent anticoagulant remains one of the most widely used clinical drugs. The primary clinical indication of heparin is for prophylactic treatment of postoperative thrombosis and acute venous thrombosis [22]. However, it has been observed that the application of heparin has exhibited multiple beneficial effects other than anticoagulation, e.g., anti-cancer and anti-inflammation properties [23]. In addition, experimental and retrospective studies showed that LMWH had anti-neoplastic effects [24,25]. These encouraging observations support the beneficial impact of heparin in treating cancer patients and chronic inflammatory diseases complicated by thrombosis.

2.2. Heparin and heparin mimetics contributions to the treatment of COVID-19 patients

One of the significant pathological symptoms of severe COVID-19 patients is hyper-coagulopathy-associated thrombosis, a leading cause of high mortality. To prevent thrombosis, WHO recommended heparin to be included in the treatment regime for hospitalized COVID-19 patients. Numerous clinical observations evidenced that treatment with heparin, primarily LMWH, reduced lethality [26,27]. As the hyper-coagulopathy is triggered by an acute immunological reaction ("cytokine storm") towards SARS-CoV-2 infection, it is assumed that heparin, apart from anticoagulation, may have also exhibited anti-inflammatory effects. Retrospective studies revealed reduced inflammatory cytokine levels were shown in COVID-19 patients treated with LMWH [28]. These findings inspire and warrant a more profound and broader investigation to explore the multiple-target effects of heparin, e.g. anticoagulation, anti-inflammation and antiviral infection, in the treatment of COVID-19 and other coronavirus infections [29]. However, it is to be noted that heparin is a potent anticoagulant, and its dosage has to be tightly regulated to avoid the risk of bleeding complications. Thus, interest is increasing in designing heparin mimetics with low or no anticoagulation activity but with high anti-inflammatory and anti-viral activity [30,31].

Heparin mimetics are highly sulfated synthetic and semi-synthetic glycosaminoglycans with different structures. *In vitro* studies from different labs demonstrated the antiviral effect of heparin mimetics [32, 33]. Many heparin-like drugs, commonly used to treat other diseases, also show good anti-SARS-CoV2 activity. For example, Pixatimod, a synthetic HS mimetic, which is in clinical trials for cancer, was found to have anti-SARS-CoV-2 activity (including those variants of concern) through disruption of the interaction between spike protein and ACE2 [34]; Pentosan polysulfate, a semisynthetic heparin-like glucosaminoglycan, which is an established drug for the oral treatment of interstitial cystitis, exhibits weaker anticoagulant effects and more potent SARS-CoV-2 inhibition than heparin in Vero cell model [35];



Fig. 1. Illustration of heparin and heparan sulfate (HS) structure.



Fig. 2. The anticoagulation activity of heparin. Antithrombin (a) has low affinity to coagulation enzymes. The conformation of AT (b) is changed after specific binding to the pentasaccharide in heparin chains, which significantly increased the affinity of AT to the coagulation enzymes (c).

Mucopolysaccharide polysulfate, a heparinoid which is a clinic drug for antithrombotic, exhibited effectively antiviral activities against wild-type or Delta S-proteins of SARS-CoV-2 than heparin in an *in vitro* cell-based assay [36]. Sulodexide, composed of a mixture of fast-moving heparin and dermatan sulfate, has been used clinically for the prevention and treatment of vascular diseases, improving the efficacy of COVID-19 patients' clinical outcomes [37]. However, discrepancies in the antiviral potencies of heparin analogs are also indicated. For instance, Gasbarri et al. revealed that SARS-CoV-2 does not use heparan sulfate for infection and the inhibition against SARS-CoV-2 was found to be simply reversible [38]. The search for novel low/non-anticoagulant heparin mimetics with the increased binding ability and fewer side effects remains a research subject.

3. Biological functions of heparan sulfate

3.1. Expression and functions

Heparan sulfate (HS) was initially discovered as a 'contaminant' or 'by-product' of heparin production from animal tissues [39–41]. The important biological functions of HS were recognized gradually when the biochemical and biological techniques were advanced. The studies during the past 40+ years have established multiple indispensable functions of HS in animal development and homeostasis, which are nicely described in several reviews [42,43]. The most direct shreds of evidence are from transgenic animal models, showing that HS is essential for animal development. Eliminating the enzymes involved in HS biosynthesis led to the production of distorted HS structure, resulting in different degrees of the developmental defect and embryonic lethality in the animals [44–47]. Due to its ubiquitous expression and structural diversity, HS interacts with diverse protein ligands, including enzymes, growth factors/morphogens and their receptors, cytokines and ECM components [48,49], enabling its participation in various biological activities, covering coordinating cellular signaling to cell-cell, cell-matrix communications. Recent studies have increasingly implicated HS in pathological processes of various diseases, such as diabetic nephropathy [50], inflammation [51,52], amyloid deposition [53,54] and tumor biology [55]. These findings imply that the molecular structure of HS may be altered under pathological conditions, resulting in abnormal biological functions.

3.2. HS as co-receptor for virus infection

HS is attached to a variety of cell surfaces as heparan sulfate proteoglycans (HSPGs), composed of a core protein and covalently linked to GAG chains. One of the well-recognized functions of HS is as coreceptors for many morphogens and growth factors, regulating key signaling activities [44]. Accumulated evidence shows that HS on cell surfaces also serves as a receptor for viral attachment and cell entry [56]. The sulfated GAG chains exhibit global negative charges that can interact electrostatically with a surface of viral or the basic residues of viral capsid proteins that are not enveloped in the virus. Viruses use these weak ionic interactions to increase their concentration at the cell surface and augment the chances of binding to more specific receptors [57,58].

Several virus species like Herpes Simplex Virus (HSV), dengue virus (DENV) [59,60], and human papillomavirus (HPV) [61,62] have the natural dependence of binding to HSPG for their attachment to the host

cells. In addition, some highly prevalent viruses could gradually adapt to HSPG after widely passaging in cells, such as foot-and-mouth disease virus (FMDV) [63], Coxsackie virus B3 (CV–B3) [64], or the Rhinoviruses-C15 (RV-C15), RV-A8, and RV-A89 [65–67]. Interestingly, other viruses such as enterovirus 71 (EV-A71) [68,69] and Cunningham polyomavirus (JCV) [70] can even obtain HSPG-binding ability *in vivo* after adapting to the host. However, for respiratory syncytial virus (RSV) [71,72] and Zika Virus (ZIKV) [73–75], the literature contains contradictory findings showing that their binding to HSPG remains controversial [58].

One solid evidence for the essential roles of HS in virus infection is Herpes Simplex Virus (HSV) infection, where it is demonstrated that a rare modification of HS described as 3-O-sulfation can interact with the envelope protein of HSV to trigger viral penetration into cells [76]. Yet, most oncogenic viruses' entry into the host is initiated by attachment to HSPG followed by important conformational changes of viral proteins and then fuses with cellular membranes. For example, Kaposi's sarcoma-associated herpes virus (KSHV) attaches primarily to HSPGs on the surface of host cells via gB and gpK8.1A [77,78], subsequently changes the conformation of viral glycoproteins to allow access to specific entry receptors. It also has been demonstrated that HSPGs expressed on the endothelial cell surface act as a receptor for HIV-1 Tat [79,80], and their binding promotes HIV neurovirulence by allowing the infection of endothelial cells that do not express CD4 and facilitating the crossing of the blood-brain barrier [81]. Furthermore, using a mouse embryonic fibroblast cell line defective in HS production, an important role of HS on Sindbis virus infection has been demonstrated through the direct interaction of envelope protein (E2) with HS [82].

Most interestingly, recent studies have provided ample evidence for the critical role of HS on SARS-CoV-2 infection [83]. Numerous associated findings support this milestone report. The study shows that human Cov-NL63 utilizes HSPG for attachment to target cells [84]. Treatment of HEK293E/ACE2-Myc cells with heparinase (degrading cell surface HS) or exogenous heparin (competing with cell surface HS) prevents viral spike protein binding to host cells. This treatment also impedes SARS pseudovirus infection, supporting the receptor roles of HS for SARS-CoV-2 attachment at the early phase of invasion [85]. Indeed, heparin and heparin mimetics are demonstrated to bind to the S1 protein receptor binding domain (RBD), leading to a conformational change



Fig. 3. Heparan sulfate serves as a receptor for viral attachment. Heparan sulfate interacts with the receptor-binding domain of spike glycoprotein, adjacent specific entry receptor, shifting the spike structure to an open conformation to facilitate ACE2 binding.

that blocks the viral attachment and/or entry, subsequently, the cellular invasion by SARS-CoV-2 (Fig. 3). Further, the molecular structure of heparin to interact with the RBD has been investigated, showing a preference in 2-O and 6-O sulfation of the polysaccharide [86].

More and more evidence suggest that HSPGs are required for virus binding to host cells, while the HS moieties on HSPGs play the key role as virus receptors. Thus, HS or HSPG could serve as an excellent broadspectrum antiviral target. Theoretically, these also provide a hint that exogenous sulfated polysaccharides may have a broad inhibition effect on virus infection.

4. Synthesis of heparin mimetics

As a front-line anticoagulant drug, the pharmaceutical production of heparin currently exceeds 100 tons/year using porcine slaughter byproducts intestinal mucosa as starting material. However, animal sources bring up major concerns in aspects of safety, environmental and supply stress. Therefore, there is an urgent need to develop non-animal source heparins to satisfy the essential need as an anticoagulant and meet the perspective for further widening the applications.

4.1. Biosynthetic enzymes for heparin and heparan sulfate

Heparin and HS are composed of alternating hexuronic acid (D-glucuronic acid (GlcA)/L-iduronic acid (IdoA)) and D-glucosamine (GlcN) that are sulfated at various positions. Heparin is exclusively found in connective tissue mast cells, while HS is expressed in all cell types. They share a common biosynthesis pathway that involves at least 11 different enzymes (Table 1). The biosynthetic process is described as two stages: 1) assembly of repeating -GlcA-GlcNAc- disaccharide units to produce the backbone of [GlcA-GlcNAc]_n structure that is accomplished by 6 different glycosyltransferases; and 2) modification of the polymers (heparosan) by five reactions catalyzed by distinct enzymes [43]. The first modification is N-deacetylation and N-sulfation of the GlcNAc units catalyzed by N-deacetylase/N-sulfotransferase (Ndst), creating substrate for the C5-epimerase (Glce) to convert GlcA to IdoA. Then the polymer serves as an optimal substrate for 2-O-sulfotransferase (Hs2st) that prefers to transfer sulfate group to the C2 of IdoA than to GlcA residues. The 6-O-sulfotransferase (Hs6st) transfers sulfate group to the C6 of GlcN, which seems less selective and can occur even before the N-sulfation (Fig. 4). The 3-O-sulfotransferase (Hs3st) adds sulfates at C3 of GlcN units, which rarely occurs in HS [87], but is critical for the anticoagulation activity in heparin. While a single gene codes Glce and Hs2st in mammalian cells, Ndst, Hs6st, and Hs3st are expressed in several isoforms [43].

4.2. Chemical synthesis

On average, the natural heparin isolated from porcine intestinal mucosa is composed of 60 mono-sugars and the size of LMWH is around 20 sugar units, which makes the chemical synthesis of these complicated carbohydrate molecules practically impossible. Nonetheless, the finding of specific binding of the pentasaccharide with antithrombin facilitated the chemical synthesis of anticoagulant oligosaccharides [88]. So far, the pentasaccharide fonduparinux is still the only synthetic oligosaccharide drug that inhibits coagulation enzymes through binding to antithrombin [89]. Although chemical synthesis of polysaccharides remains a major challenge, recent progress has been made to synthesize heparin-like oligosaccharides [90-93]. Instead of directly synthesizing an oligosaccharide, one strategy is to prepare 'building blocks', e.g. disaccharides that are linked to form a longer chain [94]. This approach was further elaborated using the 'building blocks' derived from a natural polysaccharide, e.g., heparin or HS [95]. In this way, one may build up 'tailored' oligosaccharides.

Chemically synthesized compounds are more homogeneous than those isolated from natural sources. However, restricted by the chemical

Table 1

The enzymes involved in the biosynthesis of heparin and heparan sulfate.

Enzyme	Abbreviation	Gene	Function	Reference
Xylosyltransferase	Xyl-T	XylT	Transfer xylose to core protein	[126]
Galactosyltransferase 1	Gal-T1	B4galT7	Transfer 1st galactose	[127]
Galactosyltransferase 2	Gal-T2	B3galT6	Transfer 2nd galactose	[127]
Glucuronytransferase 1	GlcA-T1	B3gat3	Transfer first glucoronic acid	[128]
N-acetylated glucusamyltransferase 1	EXTL2	Extl2	Transfer first N-acetyl glucosamine	[129]
Polymerase	EXT	Extl1/2	Transfer alternate GlcA and GlcNAc	[130]
N-deacetylase/N-sulfotransferase	NDST	Ndst1-4	N-deacetylation and sulfation of GlcNAc	[131]
Glucuorynyl C5-epimerase	Hsepi	Glce	Epimerization of GlcA to IdoA	[132]
Hexuronyl 2-O-sulfotransferase	HS2OST	Hs2st	Sulfation of IdoA and GlcA at C2	[133]
Glucosaminyl 6-O-sulfotransferase	HS6OST	Hs6st1-3	Sulfation of GlcN at C6	[134]
Glucosaminyl 3-O-sulfotransferase	HS3OST	Hs3st1-6	Sulfation of GlcN at C3	[22]



Fig. 4. Biosynthesis of heparin and heparan sulfate.

nature of sugars, synthesis difficulty increases with increased chain length concerning the protection of the hydroxyl group for each step of the reaction; therefore, there is still a bottleneck to produce sufficient quantities of oligosaccharides for pharmaceutical use. An alternative is to produce non-sugar polymers. One of the successive approaches is RAFT (Reversible Addition-Fragmentation chain Transfer) strategy to synthesize heparin-mimic polymers, generating homopolymers with molecular weights ranging from 5 to 50 kDa [96]. Among these synthetic products, the polymer with sodium 4-styrene sulfonate as the monomer and the copolymer composed of the sulfonated monomer and acrylic acid at a ratio of 1:1 show better anticoagulant activity [96].

4.3. Chemoenzymatic synthesis

Chemical synthesis has the drawbacks of multiple protection/synthesis steps, low yield and high cost, which greatly limit its practice. To avoid this, strategies for the chemoenzymatic synthesis process have been explored [36,97]. The capsular polysaccharide produced by *E. coli* K5 strain has the repeating disaccharide ($GlcA\beta1-4GlcNAc\alpha1-4$)_n structure (denoted as K5 polysaccharide) and was used as a precursor for heparin/HS. K5 polysaccharides can be modified to 'neoheparin' by

chemoenzymatic synthesis [98]. The polysaccharide, often denoted as heparosan, was chemically deacetylated and N-sulfated, then incubated with C5-epimerase to generate IdoA residues, followed by O-sulfating of various hydroxyl groups on both HexA and GlcNS residues [99,100]. The products displayed anticoagulant activity to a similar level to heparin. Unfortunately, due to the non-selective chemical O-sulfation, the reaction generated an artificial structure of non-desired sulfation at C3 of HexA that is not found in natural heparin and HS. The above procedure is advanced by an alternative strategy using O-sulfotransferases, which significantly improved selective O-sulfation reactions [101–103]. One interesting achievement is the mutational expression of one 6-O-sulfotransferase (6-OST), 6-OST Mt-4, to induce specific sulfation of the non-reducing terminal glucosamine residues [104]. In addition, N-deacetylation by chemical reaction, and enzymatic modification on human 3-O-sulfotransferase-1 (3-OST-1), successively led to the single-site sulfated heparosan, 2-deacetyl-3-O-sulfo-heparosan, which exhibits certain anti-tumor activity in vitro [105]. Although the progress in chemoenzymatic synthesis are encouraging, there is still a long way to achieve industrial-scale production.

5. Bio-production of heparin and heparin mimetics

Synthetic biology emerged at the beginning of the 21st Century and has proved to be an effective technological approach to designing and engineering biological systems for diverse applications, e.g., bioproduction of medicines, biofuels, and biomaterials. The significant progress made in synthetic biology over the last decade will continue to accelerate as design and testing cycles rely less on traditional molecular cloning tools [106]. This is an ideal strategy to produce heparin (as well as heparin mimetics) owing to its capacity and sustainability.

The biosynthesis process of heparin/HS taking place in the Golgi apparatus is believed to be highly efficient through the concerted action of each enzyme [107]. The idea is to transfer this process to a microorganism to produce polysaccharides. As discussed above, heparosan, the precursor of heparin and HS, can be produced by E. coli K5. To increase the production of heparosan and develop an alternative source of heparosan from a non-pathogenic strain, many strategies have been used, including co-expression of the key genes (such as *elmA*, *pgcA*, *gtaB* and *tuaD*) involved in heparosan synthesis, use of different chassis cells as bioreactor and optimization of culture conditions (compositions of medium and culture phase) [108–112]. Bacillus megaterium does not appear to be a very efficient chassis; with a modular approach for UDP-precursor production and pmHS1 heparosan synthesis in B. megaterium, the titer of heparosan was 237.6 mg/L [112]. By up-regulating a single precursor pathway gene UDP and expressing kfiC and kfiA glycosyltransferase genes from E. coli K5, the maximum concentration of heparosan produced by engineering B. megaterium in the bioreactor increased to 394 mg/L, further through fed-batch fermentation, the heparosan titer was increased to 1.32 g/L [113]. The non-pathogenic E. coli BL21 was also used to express heparosan; by inducing the four essential heparosan biosynthesis genes pKfiA-pKfiD in it and optimizing the cultivation process, heparosan titer reached 1.88 g/L [109], and when co-express the eliminase gene elmA, heparosan polysaccharide (about 60-100 kDa) can be cleaved into smaller oligosaccharide [114]. The most effective chassis may be B. subtilis (a recognized safe strain for industrial production), with heparosan titers reaching 5.82 g/L through up-regulation of the *tauD* gene (encoding the UDPGDH enzyme) and fermentation optimization [110,115]. However, it is still far from using E. coli K5, which has four essential genes (pKfiA-pKfiD) organized in one operon, heparosan titer up to 15 g/L in bioreactor [116,117].

These efforts are still trying to produce heparin precursors in the microorganisms. The most challenging strategy is to engineer the microorganisms to make heparin! One key point is that these post-modified enzymes acting on heparosan to produce heparin have extremely high stereoselectivity and specificity, and it's challenging to find natural enzymes that meet such conditions from microorganisms [118]. It is possible that the enzymes with high specificity or stereoselectivity can be obtained by artificially creating proteins like using "de novo design" to produce "mini proteins" (only the active domain is retained) or by rational design strategy such as the biopharmaceutical company Optimvia, using amino acid sequences to build entirely new proteins to produce heparin recently [119]. This is a step closer to the microorganism production of heparin. Nevertheless, to meet the demand for larger quantities of heparin and the potential of heparin mimetics in drug development (global market = > 100 metric tons/year) [120], we still need to work on several aspects: 1) optimizing the substrate specificity and stereoselectivity of the enzyme; 2) screening a non-toxic and genetically manipulated microbial chassis suitable for high-yielding heparin; 3) using Scale-up technology to optimize fermentation process to achieve high yield of heparin. To reach the above achievements for heparin overproduction through the desired pathways, the 5Ms strategy (including Mine, Model, Manipulation, Measure & Manufacture) could be applied (Fig. 5) [121,122]. Firstly, 'Mine' is used to clarify the internal connections in big data sets, including various omics, to generate hypotheses for 'Model'. The subsequent 'Manipulation' is



Fig. 5. Intelligent bio-production of heparin with 5Ms strategy.

applied to test the above hypotheses and figure out the feasible solution. Then 'Measure' is to uncover the phenotype of genome-modified microorganisms. These four procedures formed iterative cycles of experimentation and computation, which could be put forward for the application of 'Manufacture' [123,124]. With this 5Ms strategy, heparin and analogs could be manufactured and scaled up from the tube scale to industrial production. This system has been used for the successful overproduction of avermectins [121] and integrated multi-scale data-driven engineering to improve the production of natural products [125].

6. Concluding remarks and future perspectives

Heparin has been extensively used in research to elucidate the interactions between HS and protein ligands. As a result, more than 100 HS-binding proteins, including cytokines, growth factors and viral proteins have been identified. Thus, it is believed that heparin can modulate each of the functions of HS. Considering the significant multi-effects of heparin used to treat COVID-19, well-designed heparin mimetics could possess multi-target biological activities, including inhibition of viral infection and replication, modulation of inflammatory responses, and prevention of hyper-coagulopathy and lung damage [27,28,41].

Thus, apart from the important clinical application for the prevention and treatment of thrombosis, the accumulated experimental and clinical findings potential opens a broader venue for heparin mimetics in pharmaceutical development. However, the issue of biosafety and raw material resource limitation remains as far as heparin is exclusively extracted from animal tissues. To meet the requirements in safety, quantity and cost, bio-engineering production in microorganisms should be the most optimal approach to produce heparin. Thousands of bacterial and plant genomes revealed a tremendous breadth of previously unknown secondary metabolite biosynthetic genes. Integrated strategies of genome mining, synthetic biology, and synergistic bioactivity screening will facilitate designing a better gene circuit for an efficient bio-manufacturing of heparin in a selected microorganism.

Declaration of competing interest

The authors declare no conflict of interest.

Acknowledgements

We gratefully acknowledge the financial support from the National Key Research and Development Program of China (2021YFF0600700, 2020YFA090032 and 2019YFA0906201), the Swedish research council (2020–05759), and the National Natural Science Foundation of China (31720103901, 31961133004, 21907031, 21977029, 22108266).

References

- WHO Coronavirus (COVID-19) Dashboard. WHO coronavirus (COVID-19) dashboard with vaccination data. 2022. https://covid19.who.int/. [Accessed 15 April 2022].
- [2] Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, et al. A new coronavirus associated with human respiratory disease in China. Nature 2020;579(7798): 265–9.
- [3] Forster P, Forster L, Renfrew C, Forster M. Phylogenetic network analysis of SARS-CoV-2 genomes. Proc Natl Acad Sci U S A 2020;117(17):9241–3.
- [4] Day T, Gandon S, Lion S, Otto SP. On the evolutionary epidemiology of SARS-CoV-2. Curr Biol 2020;30(15):849–57.
- [5] He X, Hong W, Pan X, Lu G, Wei X. SARS-CoV-2 Omicron variant: characteristics and prevention. MedComm 2020;2(4):838–45. 2021.
- [6] Scudellari M. How the coronavirus infects cells and why Delta is so dangerous. Nature 2021;595(7869):640–4.
- [7] Kollias A, Kyriakoulis KG, Lagou S, Kontopantelis E, Stergiou GS, Syrigos K. Venous thromboembolism in COVID-19: a systematic review and meta-analysis. Vasc Med 2021;26(4):415–25.
- [8] Liang K, Fu Y, Kang Y, Shao H, Yang J, Cui M, et al. Clinical features of COVID-19 patients with venous thromboembolism. Clin Appl Thromb Hemost 2021;27: 10760296211013104.
- [9] Ali MAM, Spinler SA. COVID-19 and thrombosis: from bench to bedside. Trends Cardiovasc Med 2021;31(3):143–60.
- [10] Billett HH, Reyes-Gil M, Szymanski J, Ikemura K, Stahl LR, Lo Y, et al. Anticoagulation in COVID-19: effect of enoxaparin, heparin, and apixaban on mortality. Thromb Haemostasis 2020;120(12):1691–9.
- [11] Lindahl U, Li JP. Heparin an old drug with multiple potential targets in Covid-19 therapy. J Thromb Haemostasis 2020;18(9):2422–4.
- [12] Lindahl U, Li JP. Heparanase discovery and targets. Adv Exp Med Biol 2020; 1221:61–9.
- [13] Shi C, Wang C, Wang H, Yang C, Cai F, Zeng F, et al. The potential of low molecular weight heparin to mitigate cytokine storm in severe COVID-19 patients: a retrospective cohort study. Clin Transl Sci 2020;13(6):1087–95.
- [14] Xie M, Li JP. Heparan sulfate proteoglycan a common receptor for diverse cytokines. Cell Signal 2019;54:115–21.
- [15] Yu M, Zhang T, Zhang W, Sun Q, Li H, Li JP. Elucidating the interactions between heparin/heparan sulfate and SARS-CoV-2-related proteins-an important strategy for developing novel therapeutics for the COVID-19 pandemic. Front Mol Biosci 2020;7:628551.
- [16] Kim SY, Jin W, Sood A, Montgomery DW, Grant OC, Fuster MM, et al. Characterization of heparin and severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) spike glycoprotein binding interactions. Antivir Res 2020;181:104873.
- [17] Mohamed S, Coombe D. Heparin mimetics: their therapeutic potential. Pharmaceuticals 2017;10:78.
- [18] Mclean J. The thromboplastic action of heparin. J Am J Physiol 1916:41.
 [19] Lindahl U, Backstrom G, Hook M, Thunberg L, Fransson LA, Linker A. Structure of a constraint of the structure of the
- the antithrombin-binding site in heparin. Proc Natl Acad Sci USA 1979;76(7): 3198–202.
- [20] Rosenberg RD, Jordan RE, Favreau LV, Lam LH. Highly active heparin species with multiple binding sites for antithrombin. Biochem Biophys Res Commun 1979;86(4):1319–24.
- [21] Castelli R, Cassinerio E, Cappellini M, Porro F, Graziadei G, Fabris F. Heparin induced thrombocytopenia: pathogenetic, clinical, diagnostic and therapeutic aspects. Cardiovasc Hematol Disord: Drug Targets 2007;7:153–62.
- [22] Petitou M, Casu B, Lindahl U. 1976-1983, a critical period in the history of heparin: the discovery of the antithrombin binding site. Biochimie 2003;85(1–2): 83–9.
- [23] Sarah M, Mandana M, Tina K, MJAiPe Maryam. Anti-inflammatory effects of heparin and its derivatives: a systematic review. 2015. p. 1–14. 2015.
- [24] Kakkar AK, Levine MN. Thrombosis and cancer: implications beyond trousseau. J Thromb Haemostasis 2004;2(8):1261–2.
- [25] Lyman GH, Khorana AA, Kuderer NM, Lee AY, Arcelus JI, Balaban EP, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update. J Clin Oncol 2013;31(17):2189–204.
- [26] Tang N, Bai H, Chen X, Gong JL, Li DJ, Sun ZY. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemostasis 2020;18(5):1094–9.
- [27] Ayerbe L, Risco C, Ayis S. The association between treatment with heparin and survival in patients with Covid-19. J Thromb Thrombolysis 2020;50(2):298–301.
- [28] Chen S, Wang C, Wang H, Yang C, Cai F, Zeng F, et al. The potential of low molecular weight heparin to mitigate cytokine storm in severe COVID-19 patients: a retrospective clinical study. Clin Transl Sci 2020;13(6):1087–95.

- [29] Chen S, Wang T, Li JP, Sullivan MA, Wang C, Wang H, et al. Comprehensive landscape of heparin therapy for COVID-19. Carbohydr Polym 2021:117232.
- [30] Lindahl U, Li JP. Heparin an old drug with multiple potential targets in Covid-19 therapy. J Thromb Haemostasis 2020;18(9):2422–4.
- [31] Thachil J. Clinical differentiation of anticoagulant and non-anticoagulant properties of heparin. J Thromb Haemostasis 2020;18(9):2424–5.
- [32] Kim SY, Jin WH, Sood A, Montgomery DW, Grant OC, Fuster MM, et al. Characterization of heparin and severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) spike glycoprotein binding interactions. Antivir Res 2020:181.
- [33] Tandon R, Sharp JS, Zhang F, Pomin VH, Ashpole NM, Mitra D, et al. Effective inhibition of SARS-CoV-2 entry by heparin and enoxaparin derivatives. J Virol 2020;95(3):e01987. e01920.
- [34] Guimond SE, Mycroft-West CJ, Gandhi NS, Tree JA, Le TT, Spalluto CM, et al. Synthetic heparan sulfate mimetic Pixatimod (PG545) potently inhibits SARS-CoV-2 by disrupting the spike-ace2 interaction. ACS Cent Sci 2022;8(5):527–45.
- [35] Bertini S, Alekseeva A, Elli S, Pagani I, Zanzoni S, Eisele G, et al. Pentosan polysulfate inhibits attachment and infection by SARS-CoV-2 *in vitro*: insights into structural requirements for binding. Thromb Haemostasis 2022;122(6):984–97.
- [36] Zhang X, Lin L, Huang H, Linhardt RJ. Chemoenzymatic synthesis of glycosaminoglycans. Acc Chem Res 2020;53(2):335–46.
- [37] Gonzalez-Ochoa AJ, Raffetto JD, Hernández AG, Zavala N, Gutiérrez O, Vargas A, et al. Sulodexide in the treatment of patients with early stages of COVID-19: a randomized controlled trial. Thromb Haemostasis 2021;121(7):944–54.
- [38] Gasbarri M, V'Kovski P, Torriani G, Thiel V, Stellacci F, Tapparel C, et al. SARS-CoV-2 inhibition by sulfonated compounds. Microorganisms 2020;8(12):1894.
- [39] Jorpes JE, Gardell S. On heparin monosulfuric acid. J Biol Chem 1948;176(1): 267-76.
- [40] Cifonelli JA, Dorfman AJB, Communications BR. The uronic acid of heparin 1962; 7(1):41–5.
- [41] Hippensteel JA, LaRiviere WB, Colbert JF, Langouet-Astrie CJ, Schmidt EP. Heparin as a therapy for COVID-19: current evidence and future possibilities. Am J Physiol Lung Cell Mol Physiol 2020;319(2):211–7.
- [42] Bishop JR, Schuksz M, Esko JD. Heparan sulphate proteoglycans fine-tune mammalian physiology. Nature 2007;446(7139):1030–7.
- [43] Li J, Kusche Gullberg M. Heparan sulfate: biosynthesis, structure, and function. Int Rev Cell Mol Biol 2016;325:215–73.
- [44] Lin X, Wei G, Shi Z, Dryer L, Esko JD, Wells DE, et al. Disruption of gastrulation and heparan sulfate biosynthesis in EXT1-deficient mice, vol. 224; 2000. p. 299–311. 2.
- [45] Bullock S, Fletcher J, Heyningen VV, Beddington R, Wilson V. Renal agenesis in mice homozygous for a gene trap mutation in the gene encoding heparan sulphate 2-sulphotransferase. J Genetics Research 1998;12(12):1894–906.
- [46] Ringvall M, Ledin J, Holmborn K, Kuppevelt TV, Forsberg EJ. Defective heparan sulfate biosynthesis and neonatal lethality in mice lacking N-deacetylase/Nsulfotransferase-1. J Biol Chem 2000;275(34):25926–30.
- [47] Li JP, Gong F, Hagner-Mcwhirter A, Forsberg E, Abrink M, Kisilevsky R, et al. Targeted disruption of a murine glucuronyl C5-epimerase gene results in heparan sulfate lacking l-iduronic acid and in neonatal lethality. J Biol Chem 2003;278 (31):28363–6.
- [48] Lindahl U, Li JP. Interactions between heparan sulfate and proteins—design and functional implications. Int Rev Cell Mol Biol 2009;276:105–59.
- [49] Lindahl U, Kusche-Gullberg M, Kjellén L. Regulated diversity of heparan sulfate. J Biol Chem 1998;273(39):24979–82.
- [50] Raats CJ, Van Den Born J, Berden JH. Glomerular heparan sulfate alterations: mechanisms and relevance for proteinuria. Kidney Int 2000;57(2):385–400.
- [51] Wang L, Fuster M, Sriramarao P, Esko JD. Endothelial heparan sulfate deficiency impairs L-selectin- and chemokine-mediated neutrophil trafficking during inflammatory responses. Nat Immunol 2005;6(9):902–10.
- [52] Zhang X, Wang B, O'Callaghan P, Hjertström E, Jia J, Gong F, et al. Heparanase overexpression impairs inflammatory response and macrophage-mediated clearance of amyloid-β in murine brain. Acta Neuropathol 2012;124(4):465–78.
- [53] Noborn F, O'Callaghan P, Hermansson E, Zhang X, Ancsin JB, Damas AM, et al. Heparan sulfate/heparin promotes transthyretin fibrillization through selective binding to a basic motif in the protein. Proc Natl Acad Sci U S A 2011;108(14): 5584–9.
- [54] Jendresen CB, Cui H, Zhang X, Vlodavsky I, Nilsson LNG, Li JP. Overexpression of heparanase lowers the amyloid burden in amyloid-β precursor protein transgenic mice. J Biol Chem 2015;290(8):5053–64.
- [55] Escobar Galvis ML, Jia J, Zhang X, Jastrebova N, Spillmann D, Gottfridsson E, et al. Transgenic or tumor-induced expression of heparanase upregulates sulfation of heparan sulfate. Nat Chem Biol 2007;3(12):773.
- [56] Agelidis A, Shukla D. Heparanase, heparan sulfate and viral infection. Adv Exp Med Biol 2020;1221:759–70.
- [57] Rusnati M, Vicenzi E, Donalisio M, Oreste P, Landolfo S, Lembo D. Sulfated K5 *Escherichia coli* polysaccharide derivatives: a novel class of candidate antiviral microbicides. Pharmacol Ther 2009;123(3):310–22.
- [58] Cagno V, Tseligka ED, Jones ST, Tapparel C. Heparan sulfate proteoglycans and viral attachment: true receptors or adaptation bias? Viruses 2019;11(7):596.
- [59] Dalrymple N, Mackow ER. Productive dengue virus infection of human endothelial cells is directed by heparan sulfate-containing proteoglycan receptors. J Virol 2011;85(18):9478–85.
- [60] Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, et al. The global distribution and burden of dengue. Nature 2013;496(7446):504–7.
- [61] Donalisio M, Rusnati M, Civra A, Bugatti A, Allemand D, Pirri G, et al. Identification of a dendrimeric heparan sulfate-binding peptide that inhibits

infectivity of genital types of human papillomaviruses. Antimicrob Agents Chemother 2010;54(10):4290–9.

- [62] Cagno V, Donalisio M, Bugatti A, Civra A, Cavalli R, Ranucci E, et al. The agmatine-containing poly(amidoamine) polymer AGMA1 binds cell surface heparan sulfates and prevents attachment of mucosal human papillomaviruses. Antimicrob Agents Chemother 2015;59(9):5250–9.
- [63] Sa-Carvalho D, Rieder E, Baxt B, Rodarte R, Tanuri A, Mason PW. Tissue culture adaptation of foot-and-mouth disease virus selects viruses that bind to heparin and are attenuated in cattle. J Virol 1997;71(7):5115–23.
- [64] Zautner AE, Körner U, Henke A, Badorff C, Schmidtke M. Heparan sulfates and coxsackievirus-adenovirus receptor: each one mediates coxsackievirus B3 PD infection. J Virol 2003;77(18):10071–7.
- [65] Kherad O, Kaiser L, Bridevaux PO, Sarasin F, Thomas Y, Janssens JP, et al. Upperrespiratory viral infection, biomarkers, and COPD exacerbations. Chest 2010;138 (4):896–904.
- [66] Edwards MR, Bartlett NW, Hussell T, Openshaw P, Johnston SL. The microbiology of asthma. Nat Rev Microbiol 2012;10(7):459–71.
- [67] Tapparel C, Cordey S, Junier T, Farinelli L, Van Belle S, Soccal PM, et al. Rhinovirus genome variation during chronic upper and lower respiratory tract infections. PLoS One 2011;6(6):e21163.
- [68] Bochkov YA, Watters K, Ashraf S, Griggs TF, Devries MK, Jackson DJ, et al. Cadherin-related family member 3, a childhood asthma susceptibility gene product, mediates rhinovirus C binding and replication. Proc Natl Acad Sci U S A 2015;112(17):5485–90.
- [69] Tseligka ED, Sobo K, Stoppini L, Cagno V, Abdul F, Piuz I, et al. A VP1 mutation acquired during an enterovirus 71 disseminated infection confers heparan sulfate binding ability and modulates ex vivo tropism. PLoS Pathog 2018;14(8):1007190.
- [70] DeCaprio JA, Garcea RL. A cornucopia of human polyomaviruses. Nat Rev Microbiol 2013;11(4):264–76.
- [71] Crim RL, Audet SA, Feldman SA, Mostowski HS, Beeler JA. Identification of linear heparin-binding peptides derived from human respiratory syncytial virus fusion glycoprotein that inhibit infectivity. J Virol 2007;81(1):261–71.
- [72] Gilman MS, Moin SM, Mas V, Chen M, Patel NK, Kramer K, et al. Characterization of a prefusion-specific antibody that recognizes a quaternary, cleavage-dependent epitope on the RSV fusion glycoprotein. PLoS Pathog 2015;11(7):1005035.
- [73] Ghezzi S, Cooper L, Rubio A, Pagani I, Capobianchi MR, Ippolito G, et al. Heparin prevents Zika virus induced-cytopathic effects in human neural progenitor cells. Antivir Res 2017;140:13–7.
- [74] Pierson TC, Diamond MS. The emergence of Zika virus and its new clinical syndromes. Nature 2018;560(7720):573–81.
- [75] Kim SY, Koetzner CA, Payne AF, Nierode GJ, Yu Y, Wang R, et al. Glycosaminoglycan compositional analysis of relevant tissues in Zika virus pathogenesis and in vitro evaluation of heparin as an antiviral against zika virus infection. Biochemistry 2019;58(8):1155–66.
- [76] Shukla D, Liu J, Blaiklock P, Shworak NW, Bai X, Esko JD, et al. A novel role for 3-O-sulfated heparan sulfate in herpes simplex virus 1 entry. Cell 1999;99(1): 13–22.
- [77] Birkmann A, Mahr K, Ensser A, Yağuboğlu S, Titgemeyer F, Fleckenstein B, et al. Cell surface heparan sulfate is a receptor for human herpesvirus 8 and interacts with envelope glycoprotein K8.1. J Virol 2001;75(23):11583–93.
- [78] Wang FZ, Akula SM, Sharma-Walia N, Zeng L, Chandran B. Human herpesvirus 8 envelope glycoprotein B mediates cell adhesion via its RGD sequence. J Virol 2003;77(5):3131–47.
- [79] Tyagi M, Rusnati M, Presta M, Giacca M. Internalization of HIV-1 tat requires cell surface heparan sulfate proteoglycans. J Biol Chem 2001;276(5):3254–61.
- [80] Urbinati C, Nicoli S, Giacca M, David G, Fiorentini S, Caruso A, et al. HIV-1 Tat and heparan sulfate proteoglycan interaction: a novel mechanism of lymphocyte adhesion and migration across the endothelium. Blood 2009;114(15):3335–42.
- [81] Bobardt MD, Salmon P, Wang L, Esko JD, Gabuzda D, Fiala M, et al. Contribution of proteoglycans to human immunodeficiency virus type 1 brain invasion. J Virol 2004;78(12):6567–84.
- [82] Zhu W, Fu S, He Y, Li J, Liang G. Amino acid substitutions in the E2 glycoprotein of Sindbis-like virus XJ-160 confer the ability to undergo heparan sulfatedependent infection of mouse embryonic fibroblasts. Virol J 2010;7:225. 225.
- [83] Clausen TM, Sandoval DR, Spliid CB, Pihl J, Perrett HR, Painter CD, et al. SARS-CoV-2 infection depends on cellular heparan sulfate and ACE2. Cell 2020;183(4): 1043–57.
- [84] Milewska A, Zarebski M, Nowak P, Stozek K, Potempa J, Pyrc K. Human coronavirus NL63 utilizes heparan sulfate proteoglycans for attachment to target cells. J Virol 2014;88(22):13221–30.
- [85] Lang J, Yang N, Deng J, Liu K, Yang P, Zhang G, et al. Inhibition of SARS pseudovirus cell entry by lactoferrin binding to heparan sulfate proteoglycans. PLoS One 2011;6(8):23710.
- [86] Mycroft-West CJ, Su D, Pagani I, Rudd TR, Elli S, Guimond SE, et al. Heparin inhibits cellular invasion by SARS-CoV-2: structural dependence of the interaction of the surface protein (spike) S1 receptor binding domain with heparin. Thromb Haemostasis 2020;120(12):1700–15.
- [87] de Agostini AI, Dong JC, de Vantéry Arrighi C, Ramus MA, Dentand-Quadri I, Thalmann S, et al. Human follicular fluid heparan sulfate contains abundant 3-Osulfated chains with anticoagulant activity. J Biol Chem 2008;283(42):28115–24.
- [88] Petitou M, Hérault JP, Bernat A, Driguez PA, Herbert JMJN. Synthesis of thrombin-inhibiting heparin mimetics without side effects. Nature 1999;398 (6726):417–22.
- [89] Petitou M, Duchaussoy P, Herbert JM, Duc G, El Hajji M, Branellec JFO, et al. The synthetic pentasaccharide fondaparinux: first in the class of antithrombotic

agents that selectively inhibit coagulation factor Xa. Semin Thromb Hemost 2002; 28(4):393–402.

- [90] Barath M, Hansen SU, Dalton CE, Jayson GC, Miller GJ, Gardiner JM. Modular synthesis of heparin-related tetra-, hexa- and octasaccharides with differential O-6 protections: programming for regiodefined 6-O-modifications. Molecules 2015; 20(4):6167–80.
- [91] Hansen SU, Miller GJ, Cliff MJ, Jaysonc GC, Gardiner JM. Making the longest sugars: a chemical synthesis of heparin-related [4](n) oligosaccharides from 16mer to 40-mer. Chem Sci 2015;6(11):6158–64.
- [92] Roy S, El Hadri A, Richard S, Denis F, Holte K, Duffner J, et al. Synthesis and biological evaluation of a unique heparin mimetic hexasaccharide for structure-activity relationship studies. J Med Chem 2014;57(11):4511–20.
- [93] Baytas SN, Linhardt RJ. Advances in the preparation and synthesis of heparin and related products. Drug Discov Today 2020;25(12):2095–109.
- [94] Lu LD, Shie CR, Kulkarni SS, Pan GR, Lu XA, Hung SC. Synthesis of 48 disaccharide building blocks for the assembly of a heparin and heparan sulfate oligosaccharide library. Org Lett 2006;8(26):5995–8.
- [95] Pawar NJ, Wang L, Higo T, Bhattacharya C, Hsieh-Wilson LC. Expedient synthesis of core disaccharide building blocks from natural polysaccharides for heparan sulfate oligosaccharide assembly. Angew Chem Int Ed Engl 2019;58(51): 18577–83.
- [96] Nahain AA, Ignjatovic V, Monagle P, Tsanaktsidis J, Vamvounis G, Ferro V. Sulfonated RAFT copolymers as heparin mimetics: synthesis, reactivity ratios, and anticoagulant activity. Macromol Biosci 2020;20(9):e2000110.
- [97] Gottschalk J, Elling L. Current state on the enzymatic synthesis of glycosaminoglycans. Curr Opin Chem Biol 2021;61:71–80.
- [98] Lindahl U, Li JP, Kusche-Gullberg M, Salmivirta M, Alaranta S, Veromaa T, et al. Generation of "neoheparin" from *E. coli* K5 capsular polysaccharide. J Med Chem 2005;48(2):349–52.
- [99] Casu B, Grazioli G, Razi N, Guerrini M, Naggi A, Torri G, et al. Heparin-like compounds prepared by chemical modification of capsular polysaccharide from *E. coli* K5. Carbohydr Res 1994;263(2):271–84.
- [100] Datta P, Yan L, Awofiranye A, Dordick JS, Linhardt RJ. Heparosan chain characterization: sequential depolymerization of *E. coli* K5 heparosan by a bacterial eliminase heparin lyase iii and a bacterial hydrolase heparanase Bp to prepare defined oligomers. Biotechnol J 2021;16(3):2000336.
- [101] Xu Y, Masuko S, Takieddin M, Xu H, Liu R, Jing J, et al. Chemoenzymatic synthesis of homogeneous ultralow molecular weight heparins. Science 2011;334 (6055):498–501.
- [102] Liu J, Linhardt RJ. Chemoenzymatic synthesis of heparan sulfate and heparin. Nat Prod Rep 2014;31(12):1676–85.
- [103] Xu Y, Pempe EH, Liu J. Chemoenzymatic synthesis of heparin oligosaccharides with both anti-factor Xa and anti-factor IIa activities. J Biol Chem 2012;287(34): 29054–61.
- [104] Yi L, Xu Y, Kaminski AM, Chang X, Pagadala V, Horton M, et al. Using engineered 6-O-sulfotransferase to improve the synthesis of anticoagulant heparin. Org Biomol Chem 2020;18(40):8094–102.
- [105] Zha Z, Liu Y, Miao Y, Liao S, Wang SY, Tang H, et al. Preparation and characterization of 2-deacetyl-3-O-sulfo-heparosan and its antitumor effects via the fibroblast growth factor receptor pathw ay. Int J Biol Macromol 2022;201: 47–58.
- [106] Cameron DE, Bashor CJ, Collins JJ. A brief history of synthetic biology. Nat Rev Microbiol 2014;12(5):381–90.
- [107] Jacobsson I, Lindahl U. Biosynthesis of heparin. Concerted action of late polymermodification reactions. J Biol Chem 1980;255(11):5094–100.
- [108] Lohse DL, Linhardt RJ. Purification and characterization of heparin lyases from *Flavobacterium heparinum*. J Biol Chem 1992;267(34):24347–55.
- [109] Zhang C, Liu L, Teng L, Chen J, Liu J, Li J, et al. Metabolic engineering of *Escherichia coli* BL21 for biosynthesis of heparosan, a bioengineered heparin precursor. Metab Eng 2012;14(5):521–7.
- [110] Jin P, Zhang L, Yuan P, Kang Z, Du G, Chen J. Efficient biosynthesis of polysaccharides chondroitin and heparosan by metabolically engineered *Bacillus subtilis*. Carbohydr Polym 2016;140:424–32.
- [111] Sarnaik A, Abernathy MH, Han X, Ouyang Y, Xia K, Chen Y, et al. Metabolic engineering of cyanobacteria for photoautotrophic production of heparosan, a pharmaceutical precursor of heparin. Algal Res 2019;37:57–63.
- [112] Williams A, Gedeon KS, Vaidyanathan D, Yu Y, Collins CH, Dordick JS, et al. Metabolic engineering of *Bacillus megaterium* for heparosan biosynthesis using *Pasteurella multocida* heparosan synthase, PmHS2. Microb Cell Fact 2019;18(1): 132.
- [113] Nehru G, Tadi SRR, Limaye AM, Sivaprakasam S. Production and characterization of low molecular weight heparosan in *Bacillus megaterium* using *Escherichia coli* K5 glycosyltransferases. Int J Biol Macromol 2020;160:69–76.
- [114] Roy A, Miyai Y, Rossi A, Paraswar K, Desai UR, Saijoh Y, et al. Metabolic engineering of non-pathogenic *Escherichia coli* strains for the controlled production of low molecular weight heparosan and size-specific heparosan oligosaccharides. Biochim Biophys Acta Gen Subj 2021;1865(1):129765.
- [115] Van Dijl JM, Hecker M. Bacillus subtilis: from soil bacterium to super-secreting cell factory. Microb Cell Factories 2013;12:3.
- [116] Wang Z, Dordick JS, Linhardt RJ. Escherichia coli K5 heparosan fermentation and improvement by genetic engineering. Bioeng Bugs 2011;2(1):63–7.
- [117] Wang Z, Ly M, Zhang F, Zhong W, Suen A, Hickey AM, et al. *E. coli* K5 fermentation and the preparation of heparosan, a bioengineered heparin precursor. Biotechnol Bioeng 2010;107(6):964–73.
- [118] Oduah EI, Linhardt RJ, Sharfstein ST. Heparin: past, present, and future. Pharmaceuticals 2016;9(3):38.

- [119] Bioworks Ginkgo. Optimvia and ginkgo bioworks announce partnership to manufacture biosynthetic heparin. 2022. https://www.prnewswire.com/news-re leases/optimvia-and-ginkgo-bioworks-announce-partnership-to-manufacture-bio synthetic-heparin-301455332.html. [Accessed 6 January 2022].
- [120] Digital Journal. Heparin market growth to remain stable during the projection period 2019- 2027. 2022. https://www.digitaljournal.com/pr/heparin-marketgrowth-to-remain-stable-during-the-projection-period-2019-2027. [Accessed 25 April 2022].
- [121] Gao Q, Tan G-Y, Xia X, Zhang L. Learn from microbial intelligence for avermectins overproduction. Curr Opin Biotechnol 2017;48:251–7.
- [122] Li S, Wang J, Li X, Yin S, Wang W, Yang K. Genome-wide identification and evaluation of constitutive promoters in streptomycetes. Microb Cell Factories 2015;14:172.
- [123] Chen J, Liu M, Liu X, Miao J, Fu C, Gao H, et al. Interrogation of *Streptomyces avermitilis* for efficient product ion of avermectins. Synth Syst Biotechnol 2016;1 (1):7–16.
- [124] Tadmor B, Tidor B. Interdisciplinary research and education at the biologyengineering-co mputer science interface: a perspective. Drug Discov Today 2005; 10(17):1183–9.
- [125] Cao Z, Yu J, Wang W, Lu H, Xia X, Xu H, et al. Multi-scale data-driven engineering for biosynthetic titer improvement. Curr Opin Biotechnol 2020;65:205–12.
- [126] Wilson IB. The never-ending story of peptide O-xylosyltransferase. Cell Mol Life Sci 2004;61(7–8):794–809.
- [127] Almeida R, Levery SB, Mandel U, Kresse H, Schwientek T, Bennett EP, et al. Cloning and expression of a proteoglycan UDP-galactose:beta-xylose beta1,4-

galactosyltransferase I. A seventh member of the human beta4-

- galactosyltransferase gene family. J Biol Chem 1999;274(37):26165–71.
 [128] Bai X, Zhou D, Brown JR, Crawford BE, Hennet T, Esko JD. Biosynthesis of the linkage region of glycosaminoglycans: cloning and activity of galactosyltransferase II, the sixth member of the beta 1,3-galactosyltransferase family (beta 3GalT6). J Biol Chem 2001;276(51):48189–95.
- [129] Kitagawa H, Shimakawa H, Sugahara K. The tumor suppressor EXT-like gene EXTL2 encodes an alpha1, 4-N-acetylhexosaminyltransferase that transfers Nacetylgalactosamine and N-acetylglucosamine to the common glycosaminoglycan-protein linkage region. The key enzyme for the chain initiation of heparan sulfate. J Biol Chem 1999;274(20):13933–7.
- [130] Zak BM, Crawford BE, Esko JD. Hereditary multiple exostoses and heparan sulfate polymerization. Biochim Biophys Acta 2002;1573(3):346–55.
- [131] Lindahl U, Li JP. Interactions between heparan sulfate and proteins-design and functional implications. Int Rev Cell Mol Biol 2009;276:105–59.
- [132] Jacobsson I, Lindahl U, Jensen JW, Rodén L, Prihar H, Feingold DS. Biosynthesis of heparin. Substrate specificity of heparosan N-sulfate D-glucuronosyl 5epimerase. J Biol Chem 1984;259(2):1056–63.
- [133] Rong J, Habuchi H, Kimata K, Lindahl U, Kusche-Gullberg M. Substrate specificity of the heparan sulfate hexuronic acid 2-O-sulfotransferase. Biochemistry 2001;40 (18):5548–55.
- [134] Habuchi H, Miyake G, Nogami K, Kuroiwa A, Matsuda Y, Kusche-Gullberg M, et al. Biosynthesis of heparan sulphate with diverse structures and functions: two alternatively spliced forms of human heparan sulphate 6-O-sulphotransferase-2 having different expression patterns and properties. Biochem J 2003;371(Pt 1): 131–42.